( Progression Free Survival 6. Medi...)Alchemia Reports Preliminary Positive Efficacy Data From HyCAMP,Phase II Trial,Health

Progression Free Survival 6. Median Overall Survival 7. 50% or greater decline in CEA levels 8. Time to treatment failure Study Results Study Results Patient demographics Control HyCAMP(TM) Overall (n = 35) (n = 41) (n = 76) Sex Male 21 (60.0) 24 (58.5) 45 (59.2) Female 14 (40.0) 17 (41.5) 31 (40.8) Age (Years) n 35 41 76 Median 63.11 62.30 62.67 ECOG Status 0 16 19 45 1 19 22 31 Prior oxaliplatin therapy n 30 34 64 Primary Endpoint 1. Incidence of grade 3 or 4 diarrhoea in HyCAMP(TM) arm versus irinotecan arm. The overall incidence of Grade 3/4 diarrhoea (14%) was much lower than anticipated (30%) making analyses of this end point futile. There was no statistically significant difference in the incidence of grade 3 or 4 diarrhea in the HyCAMP(TM) arm versus the irinotecan arm. Secondary safety endpoints 1. Incidence of grade 3 or 4 diarrhoea in cycle 1 or cycle 2 see comment above for primary end-point all but one case of diarrhoea occurred in Cycle 1 2. Requirement for dose reduction for any cause after 2 cycles of therapy to be determined 3. Requirement for dose reduction for any reason to be determined 4. Overall incidence of grade 3 or 4 neutropenia to be determined 5. Overall adverse events - no major differences between treatment arms Secondary Efficacy Endpoints 1. Number of patients completing two cycles of therapy 38 of 41 (93%) HyCAMP(TM) patients compared to 2
'"/>




Page: 1 2 3 4 5 6 7
Related medicine technology :

1. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
2. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
3. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
4. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
5. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
6. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
7. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
8. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
9. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
10. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
11. Affymax Reports Phase 2 Clinical Dose Ranging Results of Once-Per-Month Hematide for the Treatment of Anemia